EfHNyXJuXSIZSvPJ
I love this site http://impacths.com.au/stmap_e6030.html?cialis.acarbose.voveran farmaciainpillole.com Drugmaker Retrophin Inc said it offered to buy therest of Transcept Pharmaceuticals shares it does not already ownfor $4 per share, valuing Transcept at about $75 million.Retrophin's offer represents an 11 percent premium toTranscept's closing share price of $3.59 on the Nasdaq onWednesday.
Page:[1]